iShares Neuroscience and Healthcare ETF Rating → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free IBRN Stock Alerts $23.08 -0.25 (-1.07%) (As of 06/17/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHoldingsOwnershipRatingsStock AnalysisChartHoldingsOwnershipRatings iShares Neuroscience and Healthcare ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IBRN Aggregate RatingModerate Buy2.71Holdings in IBRN have an aggregate rating of Moderate Buy based on 339 analyst ratings issued in the past year covering 42 companies (85.9% of the portfolio).IBRN Aggregate Price Target$40.1373.89% UpsideHigh Prediction$51.73Average Prediction$40.13Low Prediction$30.24Holdings in IBRN have an aggregate price target of $40.13 and a range of $30.24 to $51.73 covering 42 companies (85.9% of the portfolio).IBRN Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy22 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Neuroscience and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 42 IBRN Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.39%PTCTPTC Therapeutics$35.40-1.1%3 of 5 stars2.07$35.67 0.8%14Short Interest ↓Positive News4.85%NBIXNeurocrine Biosciences$135.29-0.1%5 of 5 stars2.80$152.00 12.4%25Positive News4.82%BIIBBiogen$226.46-2.3%5 of 5 stars2.65$286.50 26.5%26Short Interest ↓4.68%AXNXAxonics$67.28+0.1%3 of 5 stars2.38$70.30 4.5%13Positive News4.60%CERECerevel Therapeutics$41.47-0.1%0 of 5 stars2.11$42.67 2.9%94.52%SRPTSarepta Therapeutics$116.83-4.9%5 of 5 stars2.80$164.00 40.4%15Analyst ForecastPositive News4.52%ITCIIntra-Cellular Therapies$68.87+1.6%5 of 5 stars2.91$91.50 32.9%11Analyst ForecastShort Interest ↓Positive News4.51%ARGXargenx$378.30-2.2%3 of 5 stars2.80$520.68 37.6%20Analyst Forecast4.04%IARTIntegra LifeSciences$28.90-1.2%5 of 5 stars2.11$35.00 21.1%9Short Interest ↑Positive News3.80%XENEXenon Pharmaceuticals$36.60-1.7%2 of 5 stars3.00$59.11 61.5%9Positive News3.73%ALKSAlkermes$25.01+2.1%5 of 5 stars2.50$36.78 47.1%11Analyst ForecastShort Interest ↓Positive News3.23%CPRXCatalyst Pharmaceuticals$15.00-0.4%5 of 5 stars3.00$26.71 78.1%5Short Interest ↓Positive News3.20%BHVNBiohaven$32.99-2.5%3 of 5 stars3.00$55.00 66.7%8Short Interest ↑Gap Up2.93%ACADACADIA Pharmaceuticals$14.84-0.5%4 of 5 stars2.75$28.94 95.0%162.84%SUPNSupernus Pharmaceuticals$25.994 of 5 stars3.00$41.00 57.8%1Positive NewsGap Up2.64%AVDLAvadel Pharmaceuticals$15.69-0.8%2 of 5 stars3.00$24.57 56.6%72.54%DYNDyne Therapeutics$31.79-3.9%3 of 5 stars3.11$40.78 28.3%9Short Interest ↑2.19%EWTXEdgewise Therapeutics$17.37-0.8%2 of 5 stars3.00$31.20 79.6%5Positive News2.03%PRTAProthena$20.37-0.2%2 of 5 stars2.71$67.00 228.9%7Positive NewsGap Down1.59%SAVACassava Sciences$19.88+0.8%3 of 5 stars3.00$131.00 559.0%1Positive News1.17%LBPHLongboard Pharmaceuticals$18.83+1.7%2 of 5 stars3.00$42.57 126.1%7Gap Up1.06%SRRKScholar Rock$8.78-7.1%4 of 5 stars3.14$26.00 196.1%7Positive NewsGap Up1.03%WVEWave Life Sciences$5.99-3.9%4 of 5 stars2.86$11.17 86.4%7Positive News0.96%NMRANeumora Therapeutics$9.38-4.1%1 of 5 stars2.86$22.57 140.6%7News CoveragePositive News0.84%PEPGPepGen$17.37+0.7%2 of 5 stars3.00$23.00 32.4%2Gap Up0.75%VYGRVoyager Therapeutics$8.26-2.9%3 of 5 stars2.71$18.00 117.9%70.73%ANNXAnnexon$5.36-4.6%3 of 5 stars3.00$15.33 186.1%60.67%NVRONevro$8.93-1.1%2 of 5 stars1.92$19.46 117.9%13Gap Down0.64%AVXLAnavex Life Sciences$3.73-1.1%4 of 5 stars3.00$40.00 972.4%1News CoveragePositive News0.64%ALECAlector$4.57-2.4%3 of 5 stars2.57$14.00 206.3%7Short Interest ↑0.59%TRDAEntrada Therapeutics$15.21-3.6%2 of 5 stars3.00$21.00 38.1%2News CoveragePositive News0.58%DNTHDianthus Therapeutics$25.26-2.8%2 of 5 stars3.14$42.83 69.6%7Gap UpHigh Trading Volume0.58%AXGNAxoGen$7.41-3.0%3 of 5 stars3.00$10.67 43.9%3Positive News0.51%LRMRLarimar Therapeutics$7.99-14.9%2 of 5 stars3.00$21.33 167.0%6Short Interest ↓Positive News0.50%SLDBSolid Biosciences$7.47-5.4%4 of 5 stars2.86$16.00 114.2%7Positive News0.45%KYTXKyverna Therapeutics$7.89-17.2%1 of 5 stars3.00$42.75 441.8%5High Trading Volume0.44%ANROAlto Neuroscience$11.05-8.1%1 of 5 stars3.00$32.33 192.6%50.30%CAPRCapricor Therapeutics$4.96-4.1%1 of 5 stars3.00$21.75 338.5%4Short Interest ↑0.22%BWAYBrainsWay$6.03-1.6%3 of 5 stars2.67$13.00 115.6%3Gap Up0.22%ABOSAcumen Pharmaceuticals$2.50-5.3%3 of 5 stars3.00$12.00 380.0%4Short Interest ↓News CoveragePositive News0.21%ABEOAbeona Therapeutics$4.51-1.3%4 of 5 stars3.00$21.00 365.6%2Short Interest ↓0.20%CVRXCVRx$10.96+7.5%2 of 5 stars2.67$16.60 51.5%6Short Interest ↑High Trading Volume This page (NYSEARCA:IBRN) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Neuroscience and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Neuroscience and Healthcare ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
